Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to ...

The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key ...

Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting ...

It is time for the agency to start thinking like an innovator, not an impediment to innovation. By modernizing and ...

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and ...

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for ...

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA ...

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to ...

Alvotech/Teva and Biocon Biologics advanced US biosimilar access with FDA interchangeability for ustekinumab biosimilars, Selarsdi and Yesafili, plus broad 2025 formulary coverage for Biocon’s ...

Number 5: Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for ...